Biogen to Highlight Broad Research Commitment to MS Care at ECTRIMS Congress, Including New TECFIDERA® Data Demonstrating Importance of Early Treatment

Biogen (BIIB) will present new clinical data for its multiple sclerosis (MS) portfolio of therapies, including the most-prescribed oral treatment, TECFIDERA® (dimethyl fumarate), at the 31st meeting of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, 7-10 October 2015.1 TECFIDERA data will demonstrate its strong and sustained efficacy in relapsing-remitting multiple sclerosis (RRMS) among patients who were early in the course of their disease or newly diagnosed.

TECFIDERA SUCCEEDS IN PROTECTING BIOGEN'S MS MARKET SHARE FROM NOVARTIS' GILENYA

Biogen's Tecfidera is on its way to blockbuster status in the highly competitive multiple sclerosis indication. That's great news for Biogen, which needed the drug to succeed in order to protect its multibillion-dollar multiple sclerosis drug franchise.

The MS treatment market has previously been dominated by Biogen's Avonex and Tysabri, and Teva Pharmaceutical's Copaxone -- blockbuster drugs delivered by injection. Combined, those drugs generated sales of $8 billion in 2012. But, a new generation of drugs and upcoming patent expiration for Copaxone are disrupting current treatment protocols and shifting demand to new oral drugs including Novartis' Gilenya and Sanofi's  Aubagio.